BioCardia shares are lower after the company released interim efficacy results in the phase 3 pivotal CardiAMP cell therapy heart failure trial.
Portfolio Pulse from Benzinga Newsdesk
BioCardia has released interim efficacy results for its phase 3 pivotal CardiAMP cell therapy heart failure trial, causing its shares to drop.
September 05, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
BioCardia's stock price has fallen following the release of interim efficacy results for its phase 3 CardiAMP cell therapy heart failure trial.
The release of interim efficacy results for a company's product can significantly impact its stock price. In this case, the results for BioCardia's phase 3 CardiAMP cell therapy heart failure trial have led to a decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100